HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Bae, Soo Youn | - |
dc.contributor.author | Choi, Yoon La | - |
dc.contributor.author | Kim, Sangmin | - |
dc.contributor.author | Kim, Minkuk | - |
dc.contributor.author | Kim, Jiyoung | - |
dc.contributor.author | Jung, Seung Pil | - |
dc.contributor.author | Choi, Min-Young | - |
dc.contributor.author | Lee, Se Kyung | - |
dc.contributor.author | Kil, Won Ho | - |
dc.contributor.author | Lee, Jeong Eon | - |
dc.contributor.author | Nam, Seok Jin | - |
dc.date.accessioned | 2021-09-06T01:18:50Z | - |
dc.date.available | 2021-09-06T01:18:50Z | - |
dc.date.created | 2021-06-14 | - |
dc.date.issued | 2013-06 | - |
dc.identifier.issn | 0167-6806 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/103178 | - |
dc.description.abstract | Breast cancer is a highly heterogeneous malignancy. The triple-negative breast cancer (TNBC) and human epidermal growth factor receptor 2 (HER2) breast cancer subtypes are highly aggressive and are associated with a poor prognosis. The therapeutic targets for TNBC remain undefined, and many patients with the HER2 subtype acquire resistance to therapy after prolonged treatment. The objective of this study was to evaluate the prognostic significance of HER3 expression in invasive breast carcinoma. We established matched tissue microarray (TMA) blocks and clinical data from 950 cases of invasive breast carcinoma with long-term clinical follow-up data (median 109.7 months). Using the TMAs, we characterized the expression of ER, PR, HER2, EGFR, and HER3 by immunohistochemistry. Each case was classified as one of four IHC-based subtypes based on the expression of hormonal receptor (HR) and HER2. The clinicopathological characteristics and survival of 950 patients were analyzed by subtype. In the TNBC subtype, the HER3(+) group showed poorer disease-free survival (DFS, P = 0.010) and overall survival (OS, P = 0.015) than the HER3(-) group. In the HER2 subtype, the HER3(+) group also showed poorer DFS (P = 0.022) and OS (P = 0.077) than the HER3(-) group. However, there was no difference in patients with HR-positive breast cancer. HER3 expression was associated with poor DFS in both the TNBC and HER2 subtypes and poor OS in the TNBC subtype. HER3 overexpression is an important prognostic marker in hormone receptor-negative breast cancer, and further study is needed to clarify the role of HER-3 targeted treatment. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.subject | GROWTH-FACTOR RECEPTOR | - |
dc.subject | ERBB SIGNALING NETWORK | - |
dc.subject | TYROSINE KINASE | - |
dc.subject | GEFITINIB RESISTANCE | - |
dc.subject | TRASTUZUMAB | - |
dc.subject | EXPRESSION | - |
dc.subject | THERAPY | - |
dc.subject | FAMILY | - |
dc.subject | CARCINOMA | - |
dc.subject | SURVIVAL | - |
dc.title | HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Jung, Seung Pil | - |
dc.identifier.doi | 10.1007/s10549-013-2570-6 | - |
dc.identifier.scopusid | 2-s2.0-84879766749 | - |
dc.identifier.wosid | 000321070200011 | - |
dc.identifier.bibliographicCitation | BREAST CANCER RESEARCH AND TREATMENT, v.139, no.3, pp.741 - 750 | - |
dc.relation.isPartOf | BREAST CANCER RESEARCH AND TREATMENT | - |
dc.citation.title | BREAST CANCER RESEARCH AND TREATMENT | - |
dc.citation.volume | 139 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 741 | - |
dc.citation.endPage | 750 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | GROWTH-FACTOR RECEPTOR | - |
dc.subject.keywordPlus | ERBB SIGNALING NETWORK | - |
dc.subject.keywordPlus | TYROSINE KINASE | - |
dc.subject.keywordPlus | GEFITINIB RESISTANCE | - |
dc.subject.keywordPlus | TRASTUZUMAB | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | FAMILY | - |
dc.subject.keywordPlus | CARCINOMA | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordAuthor | Breast cancer | - |
dc.subject.keywordAuthor | Hormone receptor | - |
dc.subject.keywordAuthor | HER2 | - |
dc.subject.keywordAuthor | HER3 | - |
dc.subject.keywordAuthor | Prognosis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.